Cytokinetics Inc (CYTK)
70.11
-1.30
(-1.82%)
USD |
NASDAQ |
Mar 28, 16:00
70.11
0.00 (0.00%)
After-Hours: 16:37
Cytokinetics Cash from Financing (TTM): 221.32M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 221.32M |
September 30, 2023 | 82.40M |
June 30, 2023 | 417.20M |
March 31, 2023 | 415.14M |
December 31, 2022 | 516.17M |
September 30, 2022 | 505.79M |
June 30, 2022 | 417.66M |
March 31, 2022 | 417.42M |
December 31, 2021 | 319.98M |
September 30, 2021 | 304.12M |
June 30, 2021 | 229.55M |
March 31, 2021 | 230.54M |
December 31, 2020 | 234.12M |
September 30, 2020 | 351.60M |
June 30, 2020 | 137.13M |
March 31, 2020 | 155.36M |
December 31, 2019 | 159.79M |
September 30, 2019 | 39.12M |
June 30, 2019 | 37.49M |
March 31, 2019 | 18.07M |
December 31, 2018 | 13.13M |
September 30, 2018 | 14.88M |
June 30, 2018 | 6.082M |
March 31, 2018 | 109.66M |
December 31, 2017 | 225.92M |
Date | Value |
---|---|
September 30, 2017 | 224.44M |
June 30, 2017 | 223.73M |
March 31, 2017 | 117.76M |
December 31, 2016 | 16.89M |
September 30, 2016 | 39.82M |
June 30, 2016 | 39.26M |
March 31, 2016 | 38.71M |
December 31, 2015 | 23.92M |
September 30, 2015 | 9.404M |
June 30, 2015 | 9.24M |
March 31, 2015 | 9.234M |
December 31, 2014 | 48.95M |
September 30, 2014 | 47.33M |
June 30, 2014 | 46.82M |
March 31, 2014 | 54.26M |
December 31, 2013 | 14.49M |
September 30, 2013 | 6.997M |
June 30, 2013 | 7.101M |
March 31, 2013 | 55.66M |
December 31, 2012 | 58.33M |
September 30, 2012 | 60.70M |
June 30, 2012 | 60.93M |
March 31, 2012 | 24.53M |
December 31, 2011 | 21.61M |
September 30, 2011 | 24.03M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
18.07M
Minimum
Mar 2019
516.17M
Maximum
Dec 2022
260.50M
Average
232.33M
Median
Cash from Financing (TTM) Benchmarks
First Wave BioPharma Inc | 16.39M |
Bristol-Myers Squibb Co | -9.416B |
Amgen Inc | 21.05B |
Johnson & Johnson | -15.82B |
Viking Therapeutics Inc | 271.38M |